Abstract
Objectives: Reverse cholesterol transport (RCT) is a pivotal atheroprotective mechanism effectuated predominantly by apolipoprotein AI/High-density lipoprotein. In contrast to animal models, infusion of apoAI in cardiovascular (CV)-patients has not resulted in plaque regression1, potentially related to reduced local delivery in humans. To date, no data are available on delivery of apoAI in plaques. We set out to label engineered human apolipoprotein AI preβHDL particle (CER001, Cerenis) with the radio-isotope 89Zirconium (Zr) allowing for PET-CT imaging.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
